Novelix Pharmaceuticals Ltd (TRIMURTHI) — shareholding pattern, promoter holding, financials and share price
About Novelix Pharmaceuticals Ltd (TRIMURTHI)
Novelix Pharmaceuticals Ltd operates in the Healthcare Research, Analytics & Technology industry, within the Healthcare sector. It trades on the NSE as TRIMURTHI and on the BSE under scrip code 536565. Its ISIN is INE314I01036.
Incorporated in 1994, Novelix Pharmaceuticals Ltd trades in Pharmaceuticals and related products , shares, and securities [1]
Trimurthi Limited, originally a financial and securities company, transitioned into pharmaceuticals and drugs, marking significant industry diversification.
The company operates pharmacy retail outlets in Hyderabad and has expanded its operations in West Bengal and Assam, indicating a strategic geographic expansion in India.
Listed peers in Healthcare Research, Analytics & Technology: Bilcare Ltd, Jeevan Scientific Technology Ltd, Globalspace Technologies Ltd, Adeshwar Meditex Ltd, Vanta Bioscience Ltd, Docmode Health Technologies Ltd.
Valuation & Returns
10 Jul 2026At ₹66.5 a share on 10 Jul 2026, Novelix Pharmaceuticals Ltd (TRIMURTHI) was valued at a price-to-earnings ratio of -27.02x against an industry P/E of 61.73x and a price-to-book of 25.57x on a book value of ₹2.6 per share as of Mar 2022. Solomo computes return on equity of -34.44% and return on capital employed of -32.45% from filed results. Earnings ratios use consolidated results for the twelve months Dec 2021 to Sep 2022.
- P/E
- -27.02x
- Industry P/E
- 61.73x
- P/B
- 25.57x
- EPS (TTM)
- ₹-0.9
- Book value / share
- ₹2.6
- ROE
- -34.44%
- ROCE
- -32.45%
- ROA
- -29.18%
- Debt / equity
- 0.02x
- Dividend yield
- 0%
- EBITDA margin
- -59.32%
- 52-week range
- ₹38 – ₹92
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2022In the year ended Mar 2022, Novelix Pharmaceuticals Ltd (TRIMURTHI) reported revenue of ₹8.91 crore, net profit of ₹-2.03 crore and earnings per share of ₹-2.22. That compares with revenue of ₹9.59 crore and net profit of ₹-3.76 crore in Mar 2021. Figures are consolidated, as filed with the exchanges.
In the quarter ended Sep 2022, revenue was ₹1.24 crore and net profit ₹-0.15 crore (consolidated).
| Metric | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 10.51 | 10.73 | 10.85 | 9.59 | 8.91 |
| Net profit (₹ cr) | -0.35 | -0.15 | -0.26 | -3.76 | -2.03 |
| EPS (₹) | -0.43 | -0.3 | -0.35 | -4.62 | -2.22 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 47.49% | 97.11% | 231.51% | -7.09% |
| Profit growth | -1.66% | -2.28% | - | 46.01% |
| Stock price CAGR | 27% | 50% | 92% | 39% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 50.57% of Novelix Pharmaceuticals Ltd (TRIMURTHI) (up 1.14 pp QoQ). Market capitalisation was ₹189 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Sep 2013.
Largest disclosed public shareholders in Jun 2026: MALLELA VENKATRAMNA REDDY 7.66%, SESHA SAI NIKHIL CHINTALAPATI 4.05%, SRINIVASRAO SWETHA KANAKAPUR 3.63%, PANCHAGNULA VENKATA LAKSHMI NARAYANA SANKARA VARA PRASAD 2.62%, PALAKURTHI RAKESH 2.4%, SOURA INVESTMENTS HOLDINGS PRIVATE LIMITED 1.13%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 50.57% | - | - | - | 49.43% |
| Mar 2026 | 49.43% | - | - | - | 50.57% |
| Dec 2025 | 51.98% | - | - | - | 48.02% |
| Sep 2025 | 53.33% | - | - | - | 46.67% |
| Jun 2025 | 52.75% | - | - | - | 47.25% |
| Mar 2025 | 66.56% | - | - | - | 33.44% |
| Dec 2024 | 66.56% | - | - | - | 33.44% |
| Sep 2024 | 66.56% | - | - | - | 33.44% |